Impact of novel PTEN mutations in Turkish patients with glioblastoma multiforme

Journal of Neuro-Oncology

Volumn 82, Issue 3, 2007, Pages 263-269

  Tunca, Berrin ^a   Bekar, Ahmet ^a   Cecener, Gulsah ^a   Egeli, Unal ^a   Vatan, Ozgur ^a   Tolunay, Sahsine ^a   Kocaeli, Hasan ^a   Aksoy, Kaya ^b  

^a ULUDAG UNIVERSITY   (Turkey)

^b Bursa Acibadem Hospital   (Turkey)

Author keywords

Glioblastoma multiforme; Novel mutations; PTEN; Sequencing; SSCP; Turkish population

Indexed keywords

GENOMIC DNA; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE;

5' UNTRANSLATED REGION; ADULT; AGED; ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DNA SEQUENCE; EXON; FEMALE; FRAMESHIFT MUTATION; GENE FREQUENCY; GENE LOCATION; GENETIC VARIABILITY; GLIOBLASTOMA; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; INTRON; MAJOR CLINICAL STUDY; MALE; NUCLEOTIDE SEQUENCE; POINT MUTATION; PROMOTER REGION; SEQUENCE HOMOLOGY; SINGLE STRAND CONFORMATION POLYMORPHISM; TURKEY (REPUBLIC);

ADULT; AGED; BASE SEQUENCE; BRAIN NEOPLASMS; FEMALE; GLIOBLASTOMA; HUMANS; MALE; MIDDLE AGED; MUTATION; POLYMORPHISM, SINGLE-STRANDED CONFORMATIONAL; PTEN PHOSPHOHYDROLASE; TURKEY;

EID: 34247255902     PISSN: 0167594X     EISSN: 15737373     Source Type: Journal    
DOI: 10.1007/s11060-006-9293-z     Document Type: Article

References (23)

1. Turkish Ministry of Health (2000) Republic of Turkey Health Statistics, Turkish Ministry of Health. www.saglik.gov.tr/istatistikler
2. Lantos PL, Vanderberg SR, Kleihues P (1997) Tumours of the nervous system. In: Graham DI, Lantos PL (eds) Greenfield's neuropatholology, 6th edn. Arnold, pp 600-626
3. Zhou XP, Li YJ, Hoang-Xuan K, Laurent-Puig P, Mokhtari K, Longy M, Sanson M, Delattre JY, Thomas G, Hamelin R (1999) Mutational analysis of the PTEN gene in gliomas: Molecular and pathological correlations. Int J Cancer (Pred. Oncol.) 84:150-154
4. CBTRUS (2000) Statistical report: Primary brain tumors in the united states, 1992-1997, published by the central brain tumor registration of the United States
5. Ohgaki H, Dessen P, Jourde B, Hoursmann S, Nishikawa T, Di Patre PL, Burkhard C, Schüler D, Probst-Hensch NM, Maiorka PC, Baeza N, Pisani P, Yonekawa Y, Yasargil MG, Lütolf UM, Kleihues P (2004) Genetic pathways to glioblastoma: A population-based study. Cancer Res 64:6892-6899
6. Ichimura K, Ohgaki H, Kleihues P, Collins VP (2004) Molecular pathogenesis of astrocytic tumours. J Neurooncol 70:137-160
7. Collins VP (2004) Brain tumours: Classification and genes. J Neurol Neurosurg Psychiatry 75(suppl 2):2-11
8. Batchelor TT, Betensky RA, Esposito JM, Pham LD, Dorfman MV, Piscatelli N, Jhung S, Rhee D, Louis DN (2004) Age-dependent prognostic effects of genetic alterations in glioblastoma. Clin Cancer Res 10:228-233
9. Hill C, Hunter SB, Brat DJ (2003) Genetic markers in glioblastoma: prognostic significance and future therapeutic implications. Adv Anat Pathol 10:212-17
10. Ohgaki H, Kleihues P (2005) Population-based studies on incidence, survival rates, and genetic alterations in astrocytic and oligodendroglial gliomas. J Neuropathol Exp Neurol 64:479-489
11. Zhou YH, Tan F, Hess KR, Yung WKA (2003) The expression of PAX6, PTEN, vascular endothelial growth factor, and epidermal growth factor reseptor in gliomas: Relationship to tumor grade and survival. Clin Cancer Res 9:3369-3375
12. Eng C (2003) PTEN: One gene, many syndromes. Human Mutat 22:183-198
13. Kleihues P, Burger PC, Scheithauer BW (1993) Histological typing of tumors of the central nervous system. In: Kleihues P, Burger PC, Scheithaver BW (eds) International histological classification of tumors. World Health Organization, Geneva
14. Kraus JA, Glesmann N, Beck M, Krex D, Klockgether T, Schackert G, Schlegel U (2000) Molecular analysis of the PTEN, TP53, and CDKN2A tumor suppressor genes in long-term survivors of glioblastoma multiforme. J Neuroncol 48:89-94
15. Knobbe CB, Merlo A, Reifenberger F (2002) PTEN signaling in gliomas. Neurooncol 4:196-211
16. Fukushima T, Favereaux A, Huang H, Shimizu T, Yonekawa Y, Nakazato Y, Ohagki H (2006) Genetic alterations in primary glioblastomas in Japan. J Neuropathol Exp Neurol 65(1):12-18
17. www.ensembl.org/Homo_sapiens/protview?db=core;peptide=ENSP00000361021
18. Ishihara H, Sasaoka T, Kagawa S, Murakami S, Fukui K, Kawagishi Y, Yamazaki K, Sato A, Iwata M, Urakaze M, Ishiki M, Wada T, Yaguchi S, Tsuneki H, Kimura I, Kobayashi M (2003) Association of the polymorphisms in the 5′-untranslated region of PTEN gene with type 2 diabetes in a Japanase population. FEBS Lett 554:450-454
19. Agrawal S, Pilarski R, Eng C (2005) Different splicing defects lead to differential effects downstream of the lipid and protein phosphatase activities of PTEN. Human Mol Genet 14(16):2459-2468
20. Furnari FB, Lin H, Huang HJS, Cavenee WK (1997) Growth suppression of glioma cells by PTEN requires a functional phosphatase catalytic domain. Proc Natl Acad Sci USA 94:12479-12484
21. Georgescu MM, Kirsch KH, Kaloudis P, Yang H, Pavletich NP, Hanafusa H (2000) Stabilization and productive positioning roles of the C2 domain of PTEN tumor suppressor. Cancer Res 60:7033-7038
22. Georgescu MM, Kirsch KH, Akagi T, Shishido T, Hanafusa H (1999) The tumor-suppressor activity of PTEN is regulated by its carboxyl-terminal region. Proc Natl Acad Sci USA 96: 10182-10187
23. Kato H, Kato S, Kumabe T, Sonoda Y, Yoshimoto T, Kato S, Han SY, Suzuki T, Shibata H, Kanamaru R, Ishioka C (2000) Functional evaluation of p53 and PTEN gene mutations in Gliomas. Clin Cancer Res 6:3937-3943